Type of security: Fund
The data is delayed by 15 minutes.
BIB is in the long-term down -58% below S&P in 6 years.
Description: The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.
|High 52 week||70.14||Low 52 week||36.42||Last close||53.14||Last change||-1.13%|
|RSI||85.22||Average true range||2.43||Beta||2.16||Volume||382.3 K|
|Simple moving average 20 days||15.79%||Simple moving average 50 days||8.36%||Simple moving average 200 days||-6.75%|
|Performance Week||1.8%||Performance Month||11.38%||Performance Quart||-6.06%||Performance Half||-19.81%|
|Performance Year||-11.46%||Performance Year-to-date||26.25%||Volatility daily||4.67%||Volatility weekly||10.44%|
|Volatility monthly||21.39%||Volatility yearly||74.08%||Relative Volume||147.41%||Average Volume||225.48 K|
|New High||New Low|
|30-day SEC yield||Average market capitalization||Average weighted market capitalization||Forward P/E|
|Gross expense ratio||1.32%||Index dividend yield||Median market cap||Number of holdings|
|Price to Book Value||Price to Earnings||Total expense ratio||0.95%||Total net assets||347.61 M|
|Weighted market capitalization|
|Gross Expense Ratio||1,32|
|Total Expense Ratio||0,95|
|Total Net Assets||347.61 million|
|Biogen Idec Inc.||8,05|
|Gilead Sciences Inc.||7,68|
|Alexion Pharmaceuticals Inc.||6,79|
|Regeneron Pharmaceuticals Inc.||4,05|
|Vertex Pharmaceuticals Inc.||3,92|
|Biomarin Pharmaceutical Inc.||2,37|
|Health Care Products||2,54|
2019-06-25 10:50:10 | BIB Versus LABU: Comparing Leveraged Biotech ETFs
2019-05-07 16:57:08 | Biotech ETFs in Focus on String of Q1 Earnings Beats
2019-04-24 16:04:08 | Will Biotech ETFs Continue to Rally in Q1 Earnings?
2019-03-05 15:32:00 | Biotech stocks turn lower after reports of FDA commissioner resigning
2018-12-11 15:32:14 | Trump Foreshadows a Bleak Outlook for Biotech IBB, BIB
2018-10-29 09:15:01 | Stocks Still Looking for the Bottom
2018-10-19 15:47:23 | Swing Trade In Biotech Sector Gave The Best Of Both Worlds
2018-09-12 09:57:38 | Major Biotech ETFs Had Lackluster Performance in the Past Month
2018-06-15 14:55:46 | Biotech Funds Tacked On $76 Million This Week — Are They Recovering?
2018-01-10 11:07:04 | Bayer and J&J win big, Microsoft lags because of Intel, Apple turns over information
2017-12-04 16:42:15 | How Biotechs, Drugmakers Would Fare Under The Senate's Tax Bill
2017-09-15 15:26:33 | Biotech, Pharma ETFs Leave Pricing Drama Behind
2017-09-08 10:31:42 | Biotech ETF Investing is Hot, Can Get Hotter
2017-08-31 13:39:08 | Why $475,000 isn't actually that expensive for Novartis's new drug
2017-08-30 10:53:17 | Biotech ETF Investing is Starting to Look Good – Here’s Why
2017-08-25 07:37:10 | Must-Know Developments for Ionis Pharmaceuticals
2017-03-15 08:26:43 | Biotech is Bubbling Up
2017-01-30 10:24:00 | Biotech Suffered Big Outflows Again Last Week, Pushing Back A Recovery
2017-01-18 06:00:00 | Trump Foreshadows a Bleak Outlook for Biotech
2017-01-06 11:37:00 | The Most-Shorted Stocks In Health Care In 2016 Were…
2017-01-04 12:25:00 | Will Biotech Find Its Footing In 2017?
2016-12-21 10:35:45 | What Are Analysts Saying about Horizon Pharma?
2016-12-19 11:29:30 | Horizon Pharma’s Steep Fall in December: What Happened?
2016-12-09 16:14:00 | Biotech ETFs: A Short-Lived Boon From Biogen
2016-11-18 16:53:06 | Could This Stock Offer Another Profit Opportunity?
2016-11-11 17:58:33 | Letting Postelection Dust Settle For Next Opportunities
2016-10-28 11:37:12 | BUZZ-Biotech ETF weakness grows more acute
2016-10-17 12:40:31 | What Will Rising Crude Oil Inventories Mean for Crude Oil Movement?
2016-10-17 10:32:22 | Implied Volatilities: Crude Oil and Natural Gas
2016-10-14 15:06:49 | Analyzing US Crude Oil Inventories by Region: The Latest
2016-10-12 09:24:31 | Will API Inventory Report Limit Upside for Crude Oil Prices?
2016-10-11 13:03:59 | How Inventories and OPEC Decision Are Affecting Crude Prices
2016-10-10 12:30:51 | Crude Oil and Natural Gas: Analyzing Implied Volatilities
2016-10-03 17:04:36 | What Were the Implied Volatilities for Crude Oil and Natural Gas?
2016-10-03 17:04:35 | What’s the Natural Gas Outlook for This Week?
2016-09-26 11:12:22 | Options Traders: The Implied Volatility of Crude Oil and Natural Gas
2016-09-26 11:12:21 | Why the Weather Could Mean Trouble for Natural Gas Bulls
2016-09-20 14:04:06 | Buy Allows Horizon to Further Expand into Orphan Drug Space
2016-09-20 12:04:07 | How OPEC’s Decision Will Impact Crude Oil’s Movement
2016-09-19 09:30:33 | Analyzing the Implied Volatilities of Crude Oil and Natural Gas
2016-09-19 09:30:32 | Natural Gas Traders Should Watch This Weather Report
2016-09-12 11:05:01 | Crude Oil Prices Jumped as Inventories Fell
2016-09-12 09:31:08 | A Look into the Implied Volatilities of Crude Oil and Natural Gas
2016-09-12 09:31:07 | How Weather Could Be a Bullish Catalyst for Natural Gas
2016-09-06 10:26:26 | How Could the Weather Impact Natural Gas Prices?
2016-09-01 08:06:16 | What Does The Price Action in Natural Gas Indicate?
2016-08-29 15:32:03 | Implied Volatilities of Crude Oil, Natural Gas in Focus
2016-08-25 10:08:42 | What’s Driving Natural Gas Prices Higher?